Abstract:Background: Mutation of the EGFR gene is known as a predictor for the response to EGFR tyrosine kinase inhibitor. Although EGFR mutation status is proposed to be incorporated in the Ninth Edition of the Lung Cancer Staging system, its prognostic value for surgically resected lung adenocarcinoma remains controversial. Methods: Data on 1512 patients with completely resected lung adenocarcinoma who underwent EGFR mutation analysis between 2008 and 2015 were collected. The prognostic value of EGFR mutations was determined in patients with lung adenocarcinoma stratified by clinicopathologic and radiologic characteristics. Independent prognostic factors were identified by multivariate analysis using the Cox proportional hazards model. Competing risk model was used to estimate the cumulative incidence. Results: EGFR mutations were identified in 935 patients (61.8%). In the entire cohort, there was no difference in recurrence-free survival between the EGFRmutated group and the wild-type group (P = .266). However, Cox multivariate analyses revealed that EGFR mutation was a strong independent prognostic factor for worse recurrence-free survival in patients with radiologic solid tumors (hazard ratio, 1.485; 95% confidence interval, 1.208-1.826; P<.001), histologic acinar patternpredominant adenocarcinoma/papillary pattern-predominant adenocarcinoma/ invasive mucinous adenocarcinoma (hazard ratio, 1.684; 95% confidence interval, 1.330-2.132; P<.001), and pathologic stage II and III (hazard ratio, 1.417; 95% confidence interval, 1.115-1.801; P = .004). Patients with EGFR mutations developed significantly more brain (hazard ratio, 1.827; 95% confidence interval, 1.213-2.766; P = .004) and bone (hazard ratio, 1.724; 95% confidence interval, 1.131-2.631; P = .011) metastases compared with the wild-type cohort. Conclusions: EGFR mutation was a strong poor prognostic factor in patients with radiologic solid, histologic acinar pattern-predominant adenocarcinoma/papillary pattern-predominant adenocarcinoma/invasive mucinous adenocarcinoma, and pathologic stage II and III lung adenocarcinomas. After surgery, distinct metastatic patterns were revealed according to EGFR mutation status. These findings have implications for the upcoming new lung cancer staging system.

Evaluation of the prognostic value of the new 9th edition Tumor-Node-Metastases (TNM) staging system for epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients with bone metastases

Validation of the 9th edition of the TNM staging system for non-small cell lung cancer with lobectomy in stage IA–IIIA

Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non–small-cell Lung Cancer

[Introduction to the 9th edition of TNM classification for lung cancer]

Prognostic Value of Epidermal Growth Factor Receptor Gene Mutation in Resected Lung Adenocarcinoma

The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer

Recommended changes for the 8th edition of the TNM classification for lung cancer-the findings of a single-institution evaluation

Prognosis of EGFR-mutant Advanced Lung Adenocarcinoma Patients with Different Intrathoracic Metastatic Patterns

Comparison of the TNM9th and 8th editions for localized and locally advanced anal squamous cell carcinoma treated nonsurgically and proposal of a new stage grouping system

The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations

External Validation of the Eighth Edition of the TNM Classification for Lung Cancer in Small Cell Lung Cancer

Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma

Evaluation of the Eighth Edition of the American Joint Committee on Cancer TNM Staging System for Gastric Cancer: an Analysis of 7371 Patients in the SEER Database

Evaluation of the 7th Edition of the TNM Classification for Lung Cancer at a Single Institution.

New Prognostic System Specific for Epidermal Growth Factor Receptor-Mutated Lung Cancer Brain Metastasis

Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma (vol 8, pg 159, 2017)

Comparisons of prognosis prediction accuracy between modified and unmodified versions of 8th edition ypTNM

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer

Limitations and improvements of the revised tumor node metastasis (TNM) staging system of clear cell renal cell carcinoma

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer

External validation of the eighth edition of the TNM classification for lung cancer in 3,611 surgically treated patients at a single institution